Gullik Håkan Wickholm
Director/Board Member presso Beactica Therapeutics AB
Profilo
Gullik Håkan Wickholm is on the board of Beactica AB and GHW Consulting AB.
In the past he was Chief Business Officer of Lytix Biopharma AS and Head-Regional Business Development at AstraZeneca AS.
Mr. Wickholm received an undergraduate degree from the University of Uppsala.
Posizioni attive di Gullik Håkan Wickholm
Società | Posizione | Inizio |
---|---|---|
Beactica Therapeutics AB
Beactica Therapeutics AB Medical DistributorsDistribution Services Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden. | Director/Board Member | 01/01/2018 |
GHW Consulting AB | Director/Board Member | - |
Precedenti posizioni note di Gullik Håkan Wickholm
Società | Posizione | Fine |
---|---|---|
AstraZeneca AS | Corporate Officer/Principal | - |
GENOVIS AB | Director/Board Member | - |
LYTIX BIOPHARMA | Chief Executive Officer | 07/09/2017 |
Formazione di Gullik Håkan Wickholm
University of Uppsala | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
GENOVIS AB | Health Technology |
LYTIX BIOPHARMA | Health Technology |
Aziende private | 3 |
---|---|
AstraZeneca AS | |
Beactica Therapeutics AB
Beactica Therapeutics AB Medical DistributorsDistribution Services Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden. | Distribution Services |
GHW Consulting AB |